Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jul;49(7):529–532. doi: 10.1136/jcp.49.7.529

Clostridium difficile infection of the gut.

A P Dodson 1, S P Borriello 1
PMCID: PMC500563  PMID: 8813947

Full text

PDF
529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrow S. A., Croese L., Bowman R. A., Riley T. V. Evaluation of three commercial enzyme immunoassay kits for detecting faecal Clostridium difficile toxins. J Clin Pathol. 1994 Oct;47(10):954–956. doi: 10.1136/jcp.47.10.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barroso L. A., Wang S. Z., Phelps C. J., Johnson J. L., Wilkins T. D. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 1990 Jul 11;18(13):4004–4004. doi: 10.1093/nar/18.13.4004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartlett J. G. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J. 1981 Jul;149(1):6–9. [PubMed] [Google Scholar]
  4. Bartlett J. G., Moon N., Chang T. W., Taylor N., Onderdonk A. B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978 Nov;75(5):778–782. [PubMed] [Google Scholar]
  5. Borriello S. P. 12th C. L. Oakley lecture. Pathogenesis of Clostridium difficile infection of the gut. J Med Microbiol. 1990 Dec;33(4):207–215. doi: 10.1099/00222615-33-4-207. [DOI] [PubMed] [Google Scholar]
  6. Borriello S. P., Barclay F. E. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol. 1986 Jun;21(4):299–309. doi: 10.1099/00222615-21-4-299. [DOI] [PubMed] [Google Scholar]
  7. Borriello S. P. Clostridial disease of the gut. Clin Infect Dis. 1995 Jun;20 (Suppl 2):S242–S250. doi: 10.1093/clinids/20.supplement_2.s242. [DOI] [PubMed] [Google Scholar]
  8. Borriello S. P., Davies H. A., Kamiya S., Reed P. J., Seddon S. Virulence factors of Clostridium difficile. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 2):S185–S191. doi: 10.1093/clinids/12.supplement_2.s185. [DOI] [PubMed] [Google Scholar]
  9. Borriello S. P., Honour P., Turner T., Barclay F. Household pets as a potential reservoir for Clostridium difficile infection. J Clin Pathol. 1983 Jan;36(1):84–87. doi: 10.1136/jcp.36.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Borriello S. P., Larson H. E. Antibiotic and pseudomembranous colitis. J Antimicrob Chemother. 1981 Jun;7 (Suppl A):53–65. doi: 10.1093/jac/7.suppl_a.53. [DOI] [PubMed] [Google Scholar]
  11. Borriello S. P., Wren B. W., Hyde S., Seddon S. V., Sibbons P., Krishna M. M., Tabaqchali S., Manek S., Price A. B. Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun. 1992 Oct;60(10):4192–4199. doi: 10.1128/iai.60.10.4192-4199.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cartmill T. D., Panigrahi H., Worsley M. A., McCann D. C., Nice C. N., Keith E. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect. 1994 May;27(1):1–15. doi: 10.1016/0195-6701(94)90063-9. [DOI] [PubMed] [Google Scholar]
  13. DAWSON-EDWARDS P., MORRISSEY D. M. Acute enterocolitis following partial gastrectomy. Br J Surg. 1955 May;42(176):643–650. doi: 10.1002/bjs.18004217614. [DOI] [PubMed] [Google Scholar]
  14. Dane T. E., King E. G. Fatal pseudomembranous enterocolitis following clindamycin therapy. Br J Surg. 1976 Apr;63(4):305–308. doi: 10.1002/bjs.1800630413. [DOI] [PubMed] [Google Scholar]
  15. Dillon S. T., Rubin E. J., Yakubovich M., Pothoulakis C., LaMont J. T., Feig L. A., Gilbert R. J. Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun. 1995 Apr;63(4):1421–1426. doi: 10.1128/iai.63.4.1421-1426.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dove C. H., Wang S. Z., Price S. B., Phelps C. J., Lyerly D. M., Wilkins T. D., Johnson J. L. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990 Feb;58(2):480–488. doi: 10.1128/iai.58.2.480-488.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fekety R., Kim K. H., Brown D., Batts D. H., Cudmore M., Silva J., Jr Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med. 1981 Apr;70(4):906–908. doi: 10.1016/0002-9343(81)90553-2. [DOI] [PubMed] [Google Scholar]
  18. Feldman R. J., Kallich M., Weinstein M. P. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Clin Infect Dis. 1995 Jun;20(6):1560–1562. doi: 10.1093/clinids/20.6.1560. [DOI] [PubMed] [Google Scholar]
  19. George R. H., Symonds J. M., Dimock F., Brown J. D., Arabi Y., Shinagawa N., Keighley M. R., Alexander-Williams J., Burdon D. W. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978 Mar 18;1(6114):695–695. doi: 10.1136/bmj.1.6114.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Giry M., Popoff M. R., von Eichel-Streiber C., Boquet P. Transient expression of RhoA, -B, and -C GTPases in HeLa cells potentiates resistance to Clostridium difficile toxins A and B but not to Clostridium sordellii lethal toxin. Infect Immun. 1995 Oct;63(10):4063–4071. doi: 10.1128/iai.63.10.4063-4071.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goulston S. J., McGovern V. J. Pseudo-membranous colitis. Gut. 1965 Jun;6(3):207–212. doi: 10.1136/gut.6.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hammond G. A., Johnson J. L. The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog. 1995 Oct;19(4):203–213. doi: 10.1016/s0882-4010(95)90263-5. [DOI] [PubMed] [Google Scholar]
  23. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995 Jun 8;375(6531):500–503. doi: 10.1038/375500a0. [DOI] [PubMed] [Google Scholar]
  24. Just I., Selzer J., von Eichel-Streiber C., Aktories K. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest. 1995 Mar;95(3):1026–1031. doi: 10.1172/JCI117747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Larson H. E., Price A. B., Honour P., Borriello S. P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet. 1978 May 20;1(8073):1063–1066. doi: 10.1016/s0140-6736(78)90912-1. [DOI] [PubMed] [Google Scholar]
  26. Libby J. M., Donta S. T., Wilkins T. D. Clostridium difficile toxin A in infants. J Infect Dis. 1983 Sep;148(3):606–606. doi: 10.1093/infdis/148.3.606. [DOI] [PubMed] [Google Scholar]
  27. Lyerly D. M., Barroso L. A., Wilkins T. D., Depitre C., Corthier G. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun. 1992 Nov;60(11):4633–4639. doi: 10.1128/iai.60.11.4633-4639.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985 Feb;47(2):349–352. doi: 10.1128/iai.47.2.349-352.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Martinez R. D., Wilkins T. D. Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol. 1992 Jan;36(1):30–36. doi: 10.1099/00222615-36-1-30. [DOI] [PubMed] [Google Scholar]
  30. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G., Cosentini E., Feil W., Schiessel R., LaMont J. T. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995 May;95(5):2004–2011. doi: 10.1172/JCI117885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schellenberg D., Bonington A., Champion C. M., Lancaster R., Webb S., Main J. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet. 1994 Jan 15;343(8890):171–172. doi: 10.1016/s0140-6736(94)90960-1. [DOI] [PubMed] [Google Scholar]
  32. Silk D. B., Trewby P. N., Chase R. A., Mellon P. J., Hanid M. A., Davies M., Langley P. G., Wheeler P. G., Williams R. Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet. 1977 Jul 2;2(8027):1–3. doi: 10.1016/s0140-6736(77)90001-0. [DOI] [PubMed] [Google Scholar]
  33. Surawicz C. M., McFarland L. V., Elmer G., Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989 Oct;84(10):1285–1287. [PubMed] [Google Scholar]
  34. Tabaqchali S., Jumaa P. Diagnosis and management of Clostridium difficile infection. BMJ. 1995 May 27;310(6991):1375–1380. doi: 10.1136/bmj.310.6991.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tedesco F. J. Pseudomembranous colitis: pathogenesis and therapy. Med Clin North Am. 1982 May;66(3):655–664. doi: 10.1016/s0025-7125(16)31413-4. [DOI] [PubMed] [Google Scholar]
  36. Wilcox M. H., Spencer R. C. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect. 1992 Oct;22(2):85–92. doi: 10.1016/0195-6701(92)90092-z. [DOI] [PubMed] [Google Scholar]
  37. von Eichel-Streiber C., Meyer zu Heringdorf D., Habermann E., Sartingen S. Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol. 1995 Jul;17(2):313–321. doi: 10.1111/j.1365-2958.1995.mmi_17020313.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES